Iglesias JF, Muller O, Heg D, et al. - Through an investigator-initiated, multicentre, prospective, single-blind, randomized superiority trial at ten hospitals in Switzerland of 1,300 patients (1,623 lesions) aged 18 years or older with acute ST-segment elevation myocardial infarction (STEMI) who were referred for primary percutaneous coronary intervention (PCI), researchers examined the safety and efficiency of ultrathin strut biodegradable polymer sirolimus-eluting stents vs thin strut durable polymer everolimus-eluting stents in patients with acute STEMI who were undergoing primary PCI. In patients with acute STEMI undergoing primary PCI, respective to target lesion failure at 1 year, biodegradable polymer sirolimus-eluting stents were better than durable polymer everolimus-eluting stents. This variation was driven by decreased ischemia-driven target lesion revascularisation in patients treated with biodegradable polymer sirolimus-eluting stents in comparison with durable polymer everolimus-eluting stents.